ACC welcomes one education maven, waves off another

Share this article:
Joseph Green, PhD, will join the American College of Cardiology (ACC) in September as VP for professional development and chief learning officer, marking his return to academic education. He has worked as a consultant since leaving Duke University in 2004, where he was associate dean of CME.

In another senior-level staff move, Marcia Jackson, PhD, senior advisor for education, will leave the college in October, following 15 years there during which she spearheaded a strategic initiative to make ACC’s education more learner-centric. Green will pick up and expand upon her efforts.

Of his new position, Green said, “It’s really trying to do what I’ve been…writing about for years, which is linking CME to physician performance and quality of care.”

ACC has spent years developing learning resources and compiling registry data on physician performance, but new ACC chief executive Jack Lewin, MD, is making the linkage between performance measures and education a strong priority. Doctors must be able to understand their performance to meet maintenance-of-certification requirements from medical specialty boards.
“I’m not going in there to change radically anything they [ACC] have developed,” Green said. “The idea is to see if we can replicate it.”

His focus will be on improving the learning experience for the college’s 33,000 cardiologists and developing new education models, some of which may lend themselves to replication by other societies. Jackson said she plans to move into an independent consulting role.

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.